Smith EL, Zamarin D, Lesokhin AM. Harnessing the immune system for cancer therapy. Curr Opin Oncol. 2014;26:600–7.

Article  CAS  PubMed  Google Scholar 

Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118:9–16. https://doi.org/10.1038/bjc.2017.434.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Upadhaya S, Neftelino ST, Hodge JP, Oliva C, Campbell JR, Yu JX. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. Nat Rev Drug Discov NLM. 2021;20:168–9.

Article  CAS  Google Scholar 

Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24:1–11.

Article  Google Scholar 

Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:278. https://doi.org/10.1186/s40425-019-0768-9.

Article  PubMed  PubMed Central  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.

Article  PubMed  PubMed Central  Google Scholar 

Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell Elsevier. 2012;21:309–22.

Article  CAS  Google Scholar 

Yagi T, Baba Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer. Ann Surg LWW. 2019;269:471–8.

Article  Google Scholar 

Vihervuori H, Autere TA, Repo H, Kurki S, Kallio L, Lintunen MM, et al. Tumor-infiltrating lymphocytes and CD8(+) T cells predict survival of triple-negative breast cancer. J Cancer Res Clin Oncol. 2019;145:3105–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santoiemma PP, Powell DJ Jr. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther Taylor Francis. 2015;16:807–20.

Article  CAS  Google Scholar 

Loupakis F, Depetris I, Biason P, Intini R, Prete AA, Leone F, et al. Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes. Oncologist. 2020;25:481.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer Nature Publishing Group. 2011;105:93–103.

CAS  Google Scholar 

Kilshaw PJ, Higgins JMG. Alpha E: no more rejection? J Exp Med. 2002;196:873.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lehmann J, Huehn J, de la Rosa M, Maszyna F, Kretschmer U, Krenn V, et al. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. Proc Natl Acad Sci. 2002;99:13031–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johansson-Lindbom B, Svensson M, Pabst O, Palmqvist C, Marquez G, Förster R, et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med. 2005;202:1063–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park SL, Gebhardt T, Mackay LK. Tissue-resident memory T cells in cancer immunosurveillance. Trends Immunol England. 2019;40:735–47.

Article  CAS  Google Scholar 

Smazynski J, Webb JR. Resident memory-like tumor-infiltrating lymphocytes (TIL(RM)): latest players in the immuno-oncology repertoire. Front Immunol. 2018;9:1741.

Article  PubMed  PubMed Central  Google Scholar 

Mami-Chouaib F, Blanc C, Corgnac S, Hans S, Malenica I, Granier C, et al. Resident memory T cells, critical components in tumor immunology. J Immunother cancer. 2018;6:87.

Article  PubMed  PubMed Central  Google Scholar 

Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, et al. CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naïve melanoma patients and expand significantly during anti-PD-1 treatment. Clin cancer Res Off J Am Assoc Cancer Res. 2018;24:3036–45.

Article  CAS  Google Scholar 

Kol A, Lubbers JM, Terwindt ALJ, Workel HH, Plat A, Wisman GBA, et al. Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer. Oncoimmunology. 2021;10:1936391.

Article  PubMed  PubMed Central  Google Scholar 

Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Rajamanickam V, Chang SC, et al. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat Commun. 2021;12:1047.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banchereau R, Chitre AS, Scherl A, Wu TD, Patil NS, de Almeida P, et al. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade. J Immunother Cancer. 2021;9:e002231.

Article  PubMed  PubMed Central  Google Scholar 

Kim H, Jeong S, Park S, Lee YJ, Ju YS, Kim D, et al. Implication of CD69 + CD103 + Tissue‐resident‐like CD8 + T cells as a Potential Immunotherapeutic Target for Cholangiocarcinoma. Liver Int. Wiley; 2021 [cited 2021 Feb 23]; Available from: https://pubmed.ncbi.nlm.nih.gov/33548061/.

Mori T, Tanaka H, Suzuki S, Deguchi S, Yamakoshi Y, Yoshii M, et al. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer. Cancer Sci. 2021;112:1746–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paijens ST, Vledder A, Loiero D, Duiker EW, Bart J, Hendriks AM, et al. Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients. Oncoimmunology. 2021;10:1935104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chu Y, Liao J, Li J, Wang Y, Yu X, Wang J, et al. CD103+ tumor-infiltrating lymphocytes predict favorable prognosis in patients with esophageal squamous cell carcinoma. J Cancer. 2019;10:5234.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu W, Sun R, Chen L, Zheng X, Jiang J. Prognostic significance of resident CD103+ CD8+ T cells in human colorectal cancer tissues. Acta Histochem Elsevier. 2019;121:657–63.

Article  CAS  Google Scholar 

Komdeur FL, Wouters MCA, Workel HH, Tijans AM, Terwindt ALJ, Brunekreeft KL, et al. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget. 2016;7:75130–44.

Article  PubMed  PubMed Central  Google Scholar 

Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpréville V, et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 2015;194:3475–86.

Article  CAS  PubMed  Google Scholar 

Ganesan A-P, Clarke J, Wood O, Garrido-Martin EM, Chee SJ, Mellows T, et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol. 2017;18:940–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang P, Huang B, Gao Y, Yang J, Liang Z, Zhang N, et al. CD103(+)CD8(+) T lymphocytes in non-small cell lung cancer are phenotypically and functionally primed to respond to PD-1 blockade. Cell Immunol. 2018;325:48–55.

Article  CAS  PubMed  Google Scholar 

Kol A, Fan X, Wazynska MA, van Duijnhoven SMJ, Giesen D, Plat A, et al. Development of 89Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration. J Immunother Cancer BMJ Specialist J; 2022;10. Available from: https://jitc.bmj.com/content/10/12/e004877.

Shaffer T, Natarajan A, Gambhir SS. PET imaging of TIGIT expression on tumor-infiltrating lymphocytes. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27:1932–40.

Article  CAS  Google Scholar 

Echarti A, Hecht M, Büttner-Herold M, Haderlein M, Hartmann A, Fietkau R, et al. CD8+ and regulatory T cells differentiate tumor immune phenotypes and predict survival in locally advanced head and neck cancer. Cancers 2019;11.

Larimer BM, Bloch E, Nesti S, Austin EE, Wehrenberg-Klee E, Boland G, et al. The effectiveness of checkpoint inhibitor combinations and administration timing can be measured by granzyme B PET imaging. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25:1196–205.

Article  CAS  Google Scholar 

López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer Cell Elsevier. 2017;32:135–54.

Article